Mackenzie Financial’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $80.5M | Sell |
1,328,471
-116,166
| -8% | -$21.8M | 0.08% | 195 |
|
|
2026
Q1 | $282M | Buy |
1,444,637
+702,481
| +95% | +$135M | 0.34% | 68 |
|
|
2025
Q4 | $137M | Buy |
742,156
+457,855
| +161% | +$80.3M | 0.16% | 119 |
|
|
2025
Q3 | $43.6M | Buy |
284,301
+23,550
| +9% | +$3.56M | 0.05% | 269 |
|
|
2025
Q2 | $36.4M | Buy |
260,751
+59,326
| +29% | +$8.31M | 0.05% | 270 |
|
|
2025
Q1 | $29.6M | Sell |
201,425
-63,594
| -24% | -$9.2M | 0.04% | 284 |
|
|
2024
Q4 | $34.7M | Buy |
265,019
+112,252
| +73% | +$15.7M | 0.05% | 260 |
|
|
2024
Q3 | $23.8M | Sell |
152,767
-1,210
| -0.8% | -$195K | 0.03% | 317 |
|
|
2024
Q2 | $24M | Buy |
153,977
+13,106
| +9% | +$1.97M | 0.04% | 300 |
|
|
2024
Q1 | $19.1M | Sell |
140,871
-10,896
| -7% | -$1.44M | 0.03% | 345 |
|
|
2023
Q4 | $20.4M | Sell |
151,767
-5,501
| -3% | -$715K | 0.03% | 336 |
|
|
2023
Q3 | $20.8M | Sell |
157,268
-16,586
| -10% | -$2.27M | 0.04% | 312 |
|
|
2023
Q2 | $22.7M | Buy |
173,854
+9,562
| +6% | +$1.41M | 0.03% | 310 |
|
|
2023
Q1 | $22.8M | Sell |
164,292
-7,609
| -4% | -$1.02M | 0.04% | 315 |
|
|
2022
Q4 | $23.3M | Sell |
171,901
-1,880
| -1% | -$236K | 0.04% | 295 |
|
|
2022
Q3 | $19.1M | Sell |
173,781
-11,064
| -6% | -$1.4M | 0.03% | 321 |
|
|
2022
Q2 | $24.4M | Sell |
184,845
-8,548
| -4% | -$1.12M | 0.04% | 295 |
|
|
2022
Q1 | $25.7M | Buy |
193,393
+16,792
| +10% | +$2.01M | 0.03% | 311 |
|
|
2021
Q4 | $20.6M | Sell |
176,601
-1,487
| -0.8% | -$175K | 0.03% | 355 |
|
|
2021
Q3 | $21.4M | Buy |
178,088
+67,838
| +62% | +$7.9M | 0.03% | 330 |
|
|
2021
Q2 | $13.2M | Buy |
110,250
+3,650
| +3% | +$400K | 0.02% | 410 |
|
|
2021
Q1 | $10.6M | Buy |
106,600
+6,300
| +6% | +$633K | 0.02% | 413 |
|
|
2020
Q4 | $10M | Buy |
100,300
+9,100
| +10% | +$964K | 0.02% | 344 |
|
|
2020
Q3 | $10M | Buy |
91,200
+7,250
| +9% | +$806K | 0.02% | 304 |
|
|
2020
Q2 | $8.88M | Sell |
83,950
-9,450
| -10% | -$976K | 0.02% | 317 |
|
|
2020
Q1 | $8.34M | Buy |
93,400
+8,400
| +10% | +$791K | 0.03% | 293 |
|
|
2019
Q4 | $8.48M | Buy |
85,000
+3,850
| +5% | +$362K | 0.02% | 353 |
|
|
2019
Q3 | $7.23M | Buy |
81,150
+5,750
| +8% | +$499K | 0.02% | 377 |
|
|
2019
Q2 | $6.22M | Buy |
75,400
+8,185
| +12% | +$642K | 0.02% | 391 |
|
|
2019
Q1 | $5.43M | Buy |
67,215
+6,099
| +10% | +$481K | 0.01% | 500 |
|
|
2018
Q4 | $4.64M | Buy |
61,116
+46,276
| +312% | +$3.61M | 0.01% | 510 |
|
|
2018
Q3 | $1.17M | Buy |
14,840
+1,123
| +8% | +$84.9K | ﹤0.01% | 730 |
|
|
2018
Q2 | $963K | Buy |
13,717
+3,713
| +37% | +$267K | ﹤0.01% | 687 |
|
|
2018
Q1 | $700K | Sell |
10,004
-747
| -7% | -$51.7K | ﹤0.01% | 681 |
|
|
2017
Q4 | $746K | Buy |
10,751
+3,777
| +54% | +$255K | ﹤0.01% | 634 |
|
|
2017
Q3 | $473K | Buy |
6,974
+1,242
| +22% | +$78.5K | ﹤0.01% | 525 |
|
|
2017
Q2 | $391K | Buy |
5,732
+2,203
| +62% | +$144K | ﹤0.01% | 537 |
|
|
2017
Q1 | $220K | Buy |
+3,529
| New | +$205K | ﹤0.01% | 598 |
|
|
2016
Q3 | – | Sell |
-20,174
| Closed | -$1.22M | – | 665 |
|
|
2016
Q2 | $1.22M | Buy |
20,174
+279
| +1% | +$16.2K | 0.01% | 564 |
|
|
2016
Q1 | $1.12M | Sell |
19,895
-56
| -0.3% | -$3.37K | 0.01% | 483 |
|
|
2015
Q4 | $1.35M | Sell |
19,951
-295
| -1% | -$19.3K | 0.01% | 482 |
|
|
2015
Q3 | $1.29M | Buy |
20,246
+5,462
| +37% | +$359K | 0.01% | 493 |
|
|
2015
Q2 | $942K | Buy |
14,784
+191
| +1% | +$13.1K | 0.01% | 569 |
|
|
2015
Q1 | $999K | Sell |
14,593
-11,693
| -44% | -$812K | 0.01% | 551 |
|
|
2014
Q4 | $1.85M | Buy |
26,286
+1,726
| +7% | +$124K | 0.01% | 435 |
|
|
2014
Q3 | $1.75M | Buy |
+24,560
| New | +$1.8M | 0.01% | 424 |
|
Other funds holding AZN
EP
IA
Mackenzie Financial's AZN Position: Q2 2026 in Review
Mackenzie Financial reduced its AstraZeneca (AZN) stake by 8% in Q2 2026, selling an estimated $21.8M and leaving 1,328,471 shares worth $80.5M. The position accounts for 0.08% of the portfolio, ranked #195.
Mackenzie Financial first reported a position in AZN in Q3 2014 and has held it in 46 quarters since. The position peaked at $282M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Mackenzie Financial held 1,328,471 shares of AstraZeneca worth $80.5M as of Q2 2026.
- Mackenzie Financial sold 116,166 AstraZeneca shares in Q2 2026, an estimated $21.8M.
- AstraZeneca made up 0.08% of Mackenzie Financial's portfolio in Q2 2026, its #195 holding.
- Mackenzie Financial first reported a position in AstraZeneca in Q3 2014 and has held it in 46 quarters since.
- Mackenzie Financial's AstraZeneca position peaked at $282M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.